HB 710 (see similar bill HB 243) – Louisiana

Status: Inactive / Dead
Year Introduced: 2018
Link: http://www.legis.la.gov/legis/BillInfo.aspx?s=18rs&b=HB710&sbi=y

PROHIBITS A MANUFACTURER OR WHOLESALE DISTRIBUTOR FROM ENGAGING IN UNRESTRAINED PRICE INCREASES IN THE SALE OF AN ESSENTIAL OFF-PATENT OR GENERIC DRUG: authorizes the secretary of the La. Dept. Of Health to notify the attorney general of any increase in the price of an essential off-patent or generic drug if the price increase, by itself or in combination with other price increases, would result in an increase of 50% or more in the wholesale acquisition cost of the drug or the price paid by the medical assistance program for the drug within the preceding one-year period and a 30-day supply of the maximum recommended dosage of the drug for any indication or a full course of treatment with the drug, according to the label for the drug approved under the FDA would cost more than $80 at the drug’s wholesale acquisition cost.

Return to Database Search

© 2018-2019 The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found

Leave A Comment